Following the recent BRAVE-AA trials Olumiant (baricitinib) has become the first USFDA approved systemic treatment (i.e. treats the entire body rather than a specific location) for Alopecia Areata. About the new Drug (Baricitinib) Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited.

Read More

Contact Us